2,503 Shares in Stryker Co. (NYSE:SYK) Acquired by Stevens Capital Management LP

Stevens Capital Management LP purchased a new position in Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,503 shares of the medical technology company’s stock, valued at approximately $901,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banco de Sabadell S.A boosted its stake in Stryker by 1.3% during the 4th quarter. Banco de Sabadell S.A now owns 5,261 shares of the medical technology company’s stock valued at $1,897,000 after purchasing an additional 66 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Stryker during the 4th quarter valued at $660,000. KLP Kapitalforvaltning AS purchased a new stake in Stryker during the 4th quarter valued at $41,749,000. Umpqua Bank boosted its stake in Stryker by 2.7% during the 4th quarter. Umpqua Bank now owns 5,516 shares of the medical technology company’s stock valued at $2,001,000 after purchasing an additional 147 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Stryker by 11.4% during the 4th quarter. American Century Companies Inc. now owns 743,693 shares of the medical technology company’s stock valued at $267,767,000 after purchasing an additional 75,897 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Price Performance

NYSE:SYK opened at $371.38 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business’s 50-day simple moving average is $384.28 and its two-hundred day simple moving average is $374.03. The stock has a market cap of $141.71 billion, a PE ratio of 47.86, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 EPS. As a group, analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Analyst Ratings Changes

Several analysts have commented on SYK shares. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Truist Financial increased their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Finally, Citigroup reissued a “buy” rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.